Biocon: Communication regarding withholding of final dividend for the FY 2025-26
Biocon (BIOCON) filed a disclosure titled "Communication regarding withholding of final dividend for the FY 2025-26". The company is valued at about ₹55,899 crore.
What happened
Biocon (BIOCON) filed a disclosure with the exchanges on 4 November 2026 at 04:29 PM titled "Communication regarding withholding of final dividend for the FY 2025-26".
Company snapshot
Biocon is a mid-cap company in the Healthcare sector, with a market value of about ₹55,899 crore.
The stock last traded at ₹343, against a 52-week range of ₹318.4–₹447.2 (23.3% below the high).
Before this filing the shares had moved −7.5% over the month and −18.7% over three months. Average daily turnover over the last 20 sessions was about ₹99.65 crore.
Promoters held 44.68% at the end of Q1 FY27. Foreign institutions owned 8.14% and domestic institutions 23.38%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 3,942 | 31.4 | 0.26 |
| Q2 FY26 | 4,296 | 84.5 | 0.66 |
| Q3 FY26 | 4,173 | 143.8 | 1.08 |
| Q4 FY26 | 4,517 | 125.9 | 0.79 |
| Q1 FY27 | 4,336 | 141.1 | 0.87 |
What history shows
This is not the company's first dividend disclosure: BCEIE has 3 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 0.9% on average the next trading day and was down 3.3% on average after five days (3 filings with price data).
Across 27 similar disclosures by other Healthcare companies, shares moved −1.0% on average the next day and −0.5% over five days; 41% of them rose the next day.
Market-wide, 980 dividend filings with an impact score of 50 or more saw an average next-day move of +0.0%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 9 Sept 2026 | Communication regarding remittance of final dividend for the FY… | −0.2% | −4.6% |
| 28 Aug 2026 | Communication Regarding Remittance Of Final Dividend For The FY… | −2.4% | −4.8% |
| 22 Jun 2026 | Communication to the shareholders w.r.t | −0.1% | −0.7% |
What to watch
- 4 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- BIOCON: Consolidated revenue grew, but lower profit and weaker Services results tempered performance
- Biocon, Syngene in focus post-Q2 results
- Biocon Limited (BIOCON.NS) Seasonal returns chart
- Natural Biocon (India) Ltd. Estimates – BSE:NATURAL
- stock in news biocon lupin sri lotus pharma stocks action
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.